ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0133

Retention Rate of Targeted Therapies in Erdheim-Chester Disease

Corrado Campochiaro1, alessandro tomelleri1, Francesco Pegoraro2, Giovanni Galardi3, Nicola Farina4, Martina Mazzariol5, Francesco Catamerò6, Giacomo De Luca4, Giulio Cavalli4, Augusto Vaglio7 and Lorenzo Dagna8, 1IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milano, Italy, 2Department of Health Sciences, University of Florence, Firenze, Italy, 3Department of Health Sciences, University of Florence, Florence, Italy, 4IRCCS San Raffaele Hospital - Vita-Salute San Raffaele University, Milano, Italy, 5University of Turin, Torino, Italy, 6Vita-Salute San Raffaele University, Milano, Italy, 7Azienda Ospedaliero Universitaria Meyer, Parna, Italy, 8IRCCS San Raffaele Hospital and Vita-Salute San Raffaele University, Milano, Italy

Meeting: ACR Convergence 2022

Keywords: Biologicals, comparative effectiveness, Fibrosing syndromes, Inflammation, Miscellaneous Rheumatic and Inflammatory Diseases

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: Miscellaneous Rheumatic and Inflammatory Diseases Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Erdheim-Chester disease (ECD) is a rare non-Langerhans histiocytosis with a broad clinical spectrum. The therapeutic landscape of ECD has remarkably changed over the last decade following the identification of activating mutations of the MAPK-ERK pathway. Patients harboring the BRAF V600E mutation can be treated with small molecules targeting BRAF (e.g., vemurafenib and dabrafenib). MEK inhibitors (e.g., cobimetinib and trametinib) are effective in patients with other activating mutations or those refractory or intolerant to BRAF inhibitors. Though effective, these medications are associated with a significant toxicity burden. The interleukin 1 receptor antagonist anakinra has been shown to potentially decrease such adverse reactions. Retention rates of these targeted drugs (DRRs) have not yet been reported in patients with ECD.

Methods: ECD patients from two Italian referral Centres who received at least one targeted therapy were retrospectively identified. Data regarding demographics, disease characteristics, outcome, and treatment were collected. Number of targeted agents, reasons for discontinuation and previous and concomitant therapies were analyzed. DRRs at 18 months were calculated for each targeted drug. Survival curves were obtained with the Kaplan-Meier method and compared using a stratified log-rank test. Hazard ratio (HR) for concomitant anakinra treatment was evaluated.

Results: Fifty-two patients with ECD were treated with at least one targeted therapy, accounting for a total of 60 treatment courses. Demographics, disease features and treatment are shown in Table 1. Vemurafenib was the most used targeted medication (n=43 [72%]), followed by cobimetinib (n=14 [23%]), trametinib (n=2 [3%]), and dabrafenib (n=1 [2%]). The overall DRR at 18 months was 70%. DRRs did not statistically differ among vemurafenib and cobimetinib (72% versus 64%), survival curves shown in Figure 1. Trametinib and dabrafenib were not suspended throughout the entire period of observation. The most common reason of discontinuation was adverse reaction (n=13 [76%] cases). Seventeen (28%) patients received an upfront combined treatment with anakinra. As shown in Figure 1, this combination approach was associated with a significantly higher DRR (94% vs 65%, p = 0.040). Anakinra concomitant had a positive effect on DRR (HR=1.46, 95% CI=1.15-2.74)

Conclusion: In ECD patients treated with targeted therapies, the overall DRR at 18 months was over 70% and there was no difference according to the specific molecule. Combination treatment with anakinra resulted in significantly higher drug persistence.

Supporting image 1

Table 1. Main features of patients with Erdheim-Chester disease treated with targeted therapies, grouped according to the mechanism of action. Continuous and categorical variables are reported as median (interquartile range) and percentage, respectively.

Supporting image 2

Figure 1. Survival curves for the retention of targeted therapies according to the specific molecule (left) or the concomitant administration of anakinra (right)


Disclosures: C. Campochiaro, None; a. tomelleri, None; F. Pegoraro, None; G. Galardi, None; N. Farina, None; M. Mazzariol, None; F. Catamerò, None; G. De Luca, None; G. Cavalli, None; A. Vaglio, None; L. Dagna, AbbVie, AstraZeneca, Biogen, Boehringer-Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Galapagos, GSK, Janssen, Kiniksa Pharmaceuticals, Novartis, Pfizer, SOBI.

To cite this abstract in AMA style:

Campochiaro C, tomelleri a, Pegoraro F, Galardi G, Farina N, Mazzariol M, Catamerò F, De Luca G, Cavalli G, Vaglio A, Dagna L. Retention Rate of Targeted Therapies in Erdheim-Chester Disease [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/retention-rate-of-targeted-therapies-in-erdheim-chester-disease/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/retention-rate-of-targeted-therapies-in-erdheim-chester-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology